New strategies for enhancing chimeric antigen receptor (CAR) T cell therapy for cancer

增强嵌合抗原受体 (CAR) T 细胞治疗癌症的新策略

• 批准号: nhmrc : GNT1136680
• 负责人: Prof Phillip Darcy
• 金额: $ 84.95万
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-strategies-enhancing-therapy-cancer/1348062
• 关键词: New; strategies; enhancing; chimeric; antigen

The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet many patients fail to respond to this form of treatment due to low frequency of lymphocytes present at the tumor site. A new form of immunotherapy involving transfer of gene-modified lymphocytes is a potential way to overcome this problem. This project will explore new strategies to enhance the utility of this approach against blood and solid cancers.

免疫系统在癌症中的作用现在被认为非常重要，免疫治疗在患者中的成功凸显了这一点。然而，由于肿瘤部位淋巴细胞出现的频率较低，许多患者对这种治疗方式没有反应。一种涉及基因修饰淋巴细胞转移的新型免疫疗法是克服这一问题的潜在方法。该项目将探索新的策略，以增强这种方法对抗血液癌和实体癌的效用。